why choose us

First received: January 24, 2023

Clinical Trial: Deucravacitinib for the Treatment of Palmoplantar Pustulosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Palmoplantar Pustulosis

Study Type: INTERVENTIONAL


Official Title: Deucravacitinib for the Treatment of Palmoplantar Pustulosis

Brief Summary: A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP.All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.

Read more